Dac hyp compositions

A pharmaceutical composition suitable for subcutaneous administration comprising about 150 mg/mL daclizumab,

• wherein the daclizumab has one or more of the following:
• (a) an N-terminal isoform with one pyroglutamate residue and one glutamine residue that comprises 3%-17% of the total daclizumab;
• (b) an N-linked oligosaccharide profile comprising two main peaks and a minor peak, wherein one of the two main peaks is G0-GlcNAc glycoform present in about 5% to about 20% of the AUC, the other main peak is G0 glycoform present in about 70% to about 99.2% of the AUC, and the minor peak is G1 glycoform present in 1% to 9% of the AUC when determined according to the method described in Section 7.6.14;
• and
• wherein the pharmaceutical composition further comprises:
• about 5.9 mg/mL sodium succinate,
• about 0.4 mg/mL succinic acid,
• about 5.8 mg/mL sodium chloride, and
• about 0.3 mg/mL polysorbate 80, and
• wherein the pharmaceutical composition has a pH of about pH 6.0.